Quince Therapeutics (QNCX) Total Non-Current Liabilities (2022 - 2026)

Quince Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $9.2 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 80.11% year-over-year to $9.2 million in Q2 2026; TTM through Jun 2026 was $9.2 million, a 80.11% decrease from a year earlier, with the FY2025 full-year figure at $77.3 million, up 179.57% from the prior year.
• Total Non-Current Liabilities was $9.2 million for Q2 2026 at Quince Therapeutics, down from $9.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $77.3 million in Q4 2025, with the low at $3.3 million in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $28.3 million, with a median of $26.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 657.01% in 2023, then sank 80.11% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $3.3 million in 2022, then surged by 657.01% to $25.1 million in 2023, then rose by 10.08% to $27.6 million in 2024, then surged by 179.57% to $77.3 million in 2025, then plunged by 88.07% to $9.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $9.2 million (Q2 2026), $9.8 million (Q1 2026), and $77.3 million (Q4 2025), per Business Quant data.